|
1
|
Ding X, Saxena NK, Lin S, Gupta N and
Anania FA: Exendin-4, a glucagon-like protein-1 (GLP-1) receptor
agonist, reverses hepatic steatosis in ob/ob mice. Hepatology.
43:173–181. 2006. View Article : Google Scholar
|
|
2
|
Mentzel S, Dijkman HB, Van Son JP, Koene
RA and Assmann KJ: Organ distribution of aminopeptidase A and
dipeptidyl peptidase IV in normal mice. J Histochem Cytochem.
44:445–461. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heike M, Möbius U, Knuth A, Meuer S and
Meyer zum Büschenfelde KH: Tissue distribution of the T cell
activation antigen Ta1. Serological, immunohistochemical and
biochemical investigations. Clin Exp Immunol. 74:431–434.
1988.PubMed/NCBI
|
|
4
|
Gorrell MD, Gysbers V and McCaughan GW:
CD26: A multi-functional integral membrane and secreted protein of
activated lymphocytes. Scand J Immunol. 54:249–264. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dinjens WN, ten Kate J, Wijnen JT, van der
Linden EP, Beek CJ, Lenders MH, Khan PM and Bosman FT: Distribution
of adenosine deaminase-complexing protein in murine tissues. J Biol
Chem. 264:19215–19220. 1989.PubMed/NCBI
|
|
6
|
Brubaker PL and Drucker DJ:
Structure-function of the glucagon receptor family of G
protein-coupled receptors: The glucagon, GIP, GLP-1 and GLP-2
receptors. Receptors Channels. 8:179–188. 2002. View Article : Google Scholar
|
|
7
|
Reinehr T, Roth CL, Enriori PJ and Masur
K: Changes of dipeptidyl peptidase IV (DPP-IV) in obese children
with weight loss: Relationships to peptide YY, pancreatic peptide
and insulin sensitivity. J Pediatr Endocrinol Metab. 23:101–108.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamabe T, Takakura K, Sugie K, Kitaoka Y,
Takeda S, Okubo Y, Teshigawara K, Yodoi J and Hori T: Induction of
the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural
killer cells by IL-2, IL-12 or IL-15. Immunology. 91:151–158. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ohnuma K, Takahashi N, Yamochi T, Hosono
O, Dang NH and Morimoto C: Role of CD26/dipeptidyl peptidase IV in
human T cell activation and function. Front Biosci. 13:2299–2310.
2008. View Article : Google Scholar
|
|
10
|
Conarello SL, Li Z, Ronan J, Roy RS, Zhu
L, Jiang G, Liu F, Woods J, Zycband E, Moller DE, et al: Mice
lacking dipeptidyl peptidase IV are protected against obesity and
insulin resistance. Proc Natl Acad Sci USA. 100:6825–6830. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Itou M, Kawaguchi T, Taniguchi E and Sata
M: Dipeptidyl peptidase-4: A key player in chronic liver disease.
World J Gastroenterol. 19:2298–2306. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miyazaki M, Kato M, Tanaka K, Tanaka M,
Kohjima M, Nakamura K, Enjoji M, Nakamuta M, Kotoh K and Takayanagi
R: Increased hepatic expression of dipeptidyl peptidase-4 in
non-alcoholic fatty liver disease and its association with insulin
resistance and glucose metabolism. Mol Med Rep. 5:729–733.
2012.
|
|
13
|
Balaban YH, Korkusuz P, Simsek H, Gokcan
H, Gedikoglu G, Pinar A, Hascelik G, Asan E, Hamaloglu E and Tatar
G: Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol.
6:242–250. 2007.PubMed/NCBI
|
|
14
|
Ben-Shlomo S, Zvibel I, Shnell M, Shlomai
A, Chepurko E, Halpern Z, Barzilai N, Oren R and Fishman S:
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation
of AMP-activated protein kinase. J Hepatol. 54:1214–1223. 2011.
View Article : Google Scholar
|
|
15
|
Soga M, Kishimoto Y, Kawaguchi J, Nakai Y,
Kawamura Y, Inagaki S, Katoh K, Oohara T, Makino S and Oshima I:
The FLS mouse: A new inbred strain with spontaneous fatty liver.
Lab Anim Sci. 49:269–275. 1999.PubMed/NCBI
|
|
16
|
Soga M, Hashimoto S, Kishimoto Y, Hirasawa
T, Makino S and Inagaki S: Insulin resistance, steatohepatitis and
hepatocellular carcinoma in a new congenic strain of Fatty Liver
Shionogi (FLS) mice with the Lep (ob) gene. Exp Anim. 59:407–419.
2010. View Article : Google Scholar
|
|
17
|
Sugihara T, Koda M, Kishina M, Kato J,
Tokunaga S, Matono T, Ueki M and Murawaki Y: Fatty liver Shionogi
ob/ob mouse: A new candidate for a non-alcoholic steatohepatitis
model. Hepatol Res. 43:547–556. 2013. View Article : Google Scholar
|
|
18
|
Jung YA, Choi YK, Jung GS, Seo HY, Kim HS,
Jang BK, Kim JG, Lee IK, Kim MK and Park KG: Sitagliptin attenuates
methionine/choline-deficient diet-induced steatohepatitis. Diabetes
Res Clin Pract. 105:47–57. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McKnight AJ, Macfarlane AJ, Dri P, Turley
L, Willis AC and Gordon S: Molecular cloning of F4/80, a murine
macrophage-restricted cell surface glycoprotein with homology to
the G-protein-linked transmembrane 7 hormone receptor family. J
Biol Chem. 271:486–489. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data usingreal-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
21
|
Tilg H and Moschen AR: Evolution of
inflammation in nonalcoholic fatty liver disease: The multiple
parallel hits hypothesis. Hepatology. 52:1836–1846. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tessari P, Coracina A, Cosma A and Tiengo
A: Hepatic lipid metabolism and non-alcoholic fatty liver disease.
Nutr Metab Cardiovasc Dis. 19:291–302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Angulo P: Nonalcoholic fatty liver
disease. N Engl J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Youssef W and McCullough AJ: Diabetes
mellitus, obesity and hepatic steatosis. Semin Gastrointest Dis.
13:17–30. 2002.PubMed/NCBI
|
|
25
|
Ballantyne GH: Peptide YY(1–36) and
peptide YY(3–36): Part I. Distribution, release and actions. Obes
Surg. 16:651–658. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Matikainen N, Mänttäri S, Schweizer A,
Ulvestad A, Mills D, Dunning BE, Foley JE and Taskinen MR:
Vildagliptin therapy reduces postprandial intestinal
triglyceride-rich lipoprotein particles in patients with type 2
diabetes. Diabetologia. 49:2049–2057. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scott R, Loeys T, Davies MJ and Engel SS;
Sitagliptin Study 801 Group: Efficacy and safety of sitagliptin
when added to ongoing metformin therapy in patients with type 2
diabetes. Diabetes Obes Metab. 10:959–969. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schreuder TC, Verwer BJ, van Nieuwkerk CM
and Mulder CJ: Nonalcoholic fatty liver disease: An overview of
current insights in pathogenesis, diagnosis and treatment. World J
Gastroenterol. 14:2474–2486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shirakawa J, Fujii H, Ohnuma K, Sato K,
Ito Y, Kaji M, Sakamoto E, Koganei M, Sasaki H, Nagashima Y, et al:
Diet-induced adipose tissue inflammation and liver steatosis are
prevented by DPP-4 inhibition in diabetic mice. Diabetes.
60:1246–1257. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Foley JE and Jordan J: Weight neutrality
with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and
clinical experience. Vasc Health Risk Manag. 6:541–548. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Foufelle F and Ferré P: New perspectives
in the regulation of hepatic glycolytic and lipogenic genes by
insulin and glucose: A role for the transcription factor sterol
regulatory element binding protein-1c. Biochem J. 366:377–391.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bugianesi E, MuCullough AJ and Marchesini
G: Insulin resistance: A metabolic pathway to chronic liver
disease. Hepatology. 42:987–1000. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim D, Wang L, Beconi M, Eiermann GJ,
Fisher MH, He H, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, et
al: (2R)-4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)
triazolo(4,3-a) pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)
butan-2-amine: A potent, orally active dipeptidyl peptidase IV
inhibitor for the treatment of type 2 diabetes. J Med Chem.
48:141–151. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wetterau JR, Lin MC and Jamil H:
Microsomal triglyceride transfer protein. Biochim Biophys Acta.
1345:136–150. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zamara E, Galastri S, Aleffi S, Petrai I,
Aragno M, Mastrocola R, Novo E, Bertolani C, Milani S, Vizzutti F,
et al: Prevention of severe toxic liver injury and oxidative stress
in MCP-1-deficient mice. J Hepatol. 46:230–238. 2007. View Article : Google Scholar
|
|
36
|
Seki E, de Minicis S, Inokuchi S, Taura K,
Miyai K, van Rooijen N, Schwabe RF and Brenner DA: CCR2 promotes
hepatic fibrosis in mice. Hepatology. 50:185–197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Galastri S, Zamara E, Milani S, Novo E,
Provenzano A, Delogu W, Vizzutti F, Sutti S, Locatelli I, Navari N,
et al: Lack of CC chemokine ligand 2 differentially affects
inflammation and fibrosis according to the genetic background in a
murine model of steatohepatitis. Clin Sci (Lond). 123:459–471.
2012. View Article : Google Scholar
|
|
38
|
Fadini GP, Boscaro E, Albiero M, Menegazzo
L, Frison V, de Kreutzenberg S, Agostini C, Tiengo A and Avogaro A:
The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases
circulating endothelial progenitor cells in patients with type 2
diabetes: Possible role of stromal-derived factor-1alpha. Diabetes
Care. 33:1607–1609. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kaji K, Yoshiji H, Ikenaka Y, Noguchi R,
Aihara Y, Douhara A, Moriya K, Kawaratani H, Shirai Y, Yoshii J, et
al: Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis
via suppression of activated hepatic stellate cell in rats. J
Gastroenterol. 49:481–491. 2013. View Article : Google Scholar : PubMed/NCBI
|
